Compare SLNH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLNH | BDTX |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.7M | 104.0M |
| IPO Year | 2005 | 2020 |
| Metric | SLNH | BDTX |
|---|---|---|
| Price | $0.55 | $1.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $2.75 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 11.7M | 845.5K |
| Earning Date | 11-20-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 80.41 | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,021,000.00 | N/A |
| Revenue This Year | $106.45 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 80.49 | N/A |
| 52 Week Low | $0.45 | $1.60 |
| 52 Week High | $2.55 | $4.94 |
| Indicator | SLNH | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 52.35 |
| Support Level | N/A | $1.65 |
| Resistance Level | $0.73 | $1.93 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 36.37 | 50.00 |
Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.